Market Place
Sourcing Support
BMS scores tumour-agnostic nod for Augtyro across NTRK fusion cancers
14 Jun 2024 //
PRESS RELEASE
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib)
13 Jun 2024 //
BUSINESSWIRE
Zai Lab ROS1 NSCLC Drug AUGTYRO Approved In China
12 May 2024 //
BUSINESSWIRE
FDA Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro
14 Feb 2024 //
BUSINESSWIRE
EMA Validates Bristol Myers Squibb’s Application for Repotrectinib
02 Jan 2024 //
BUSINESSWIRE
US FDA approves Bristol-Myers` lung cancer drug
16 Nov 2023 //
BUSINESSWIRE
Repotrectinib Gets Breakthrough Therapy Designation in China for NTRK+ TKI
31 Aug 2023 //
ONCLIVE
NMPA grants breakthrough therapy designation to Zai Lab’s repotrectinib
31 Aug 2023 //
PHARMACEUTICAL TECHNOLOGY
Repotrectinib Shows 35.7 Month Median PFS In Lung Cancer: Oral Presentation
17 Aug 2023 //
PRESS RELEASE
Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib
16 Aug 2023 //
BUSINESSWIRE
Zai Lab Announces NDA Acceptance of Repotrectinib for ROS1-positive NSCLC
28 Jun 2023 //
PRESS RELEASE
BMS nabs priority review for repotrectinib in non-small-cell lung cancer
30 May 2023 //
PRESS RELEASE
FDA Accepts for Priority Review BMS’s Application for Repotrectinib
30 May 2023 //
BUSINESSWIRE
Turning Point Provides Regulatory Update for Repotrectinib for ROS1+ Adv NSCLC
27 Jul 2022 //
GLOBENEWSWIRE
BMS to acquire cancer drugmaker Turning Point for $4.1bn
04 Jun 2022 //
FT
Turning Point Therapeutics Granted BTD for Repotrectinib Treatment
10 May 2022 //
GLOBENEWSWIRE
Turning Point Shows Positive Topline Data for Repotrectinib in PI/II Study
12 Apr 2022 //
GLOBENEWSWIRE
Zai Lab Announces BTD Granted for Repotrectinib in China
17 Feb 2022 //
PRESS RELEASE
Turning Point Granted Breakthrough Therapy Designation for Repotrectinib
04 Oct 2021 //
GLOBENEWSWIRE
Turning Point Granted Breakthrough Therapy Designation for Repotrectinib
04 Oct 2021 //
GLOBENEWSWIRE
Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study
16 Aug 2021 //
GLOBENEWSWIRE
Turning Point Reports Updated Interim Data From Registrational Phase 2 Trident
29 Jan 2021 //
GLOBENEWSWIRE
Turning Point Granted FDA Breakthrough Therapy Designation for Repotrectinib
08 Dec 2020 //
GLOBENEWSWIRE
Turning Point Announces Abstract For TRIDENT-1 Study of Repotrectinib
21 Oct 2020 //
GLOBENEWSWIRE
Turning Point Reports Early Interim Data Ph 2 Trident-1 Study Repotrectinib,
19 Aug 2020 //
TPTHERAPEUTICS
Turning Point touts positive pivotal NSCLC data, hints at even faster OK
19 Aug 2020 //
ENDPOINTSNEWS
Clinical Cancer Research Highlights Potent Antitumor Activity of Repotrectinib
16 Apr 2020 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.